[Form 3] Gelteq Ltd Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Gelteq Ltd filed an initial insider ownership report naming Paul Michael Wynne as a reporting person in his role as Chief Scientific Officer. This Form 3 establishes him as a company insider for disclosure purposes. The data shown includes no reported purchases, sales, acquisitions, or dispositions of Gelteq Ltd securities.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

WYNNE Paul Michael

(Last) (First) (Middle)

C/O GELTEQ LIMITED

LEVEL 19 644 CHAPEL ROAD

(Street)

SOUTH YARRA VIC 3141

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Gelteq Ltd [ GELS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Paul Michael Wynne	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Gelteq Ltd (GELS) Form 3 for Paul Michael Wynne show?

The Form 3 identifies Paul Michael Wynne as a reporting person and Chief Scientific Officer of Gelteq Ltd. It classifies him as an insider for SEC disclosure, with no transactions reported in the provided data.

Does the Gelteq Ltd (GELS) Form 3 show any insider buying or selling?

No insider buying or selling appears in the provided Form 3 data. The transaction summary shows zero buys, sells, acquisitions, or dispositions, indicating no reportable trades are included in this excerpt.

Who is the reporting person in the Gelteq Ltd (GELS) Form 3 filing?

The reporting person is Paul Michael Wynne, who serves as Chief Scientific Officer of Gelteq Ltd. His role is flagged as an officer, while he is not listed as a director or ten percent owner in this data.

What is the purpose of Gelteq Ltd (GELS) filing this Form 3?

The Form 3 serves as an initial statement of beneficial ownership for insider reporting. It formally registers Paul Michael Wynne, Gelteq Ltd’s Chief Scientific Officer, as a person whose future transactions in company securities must be disclosed.

Are there any derivative securities reported in the Gelteq Ltd (GELS) Form 3?

No derivative securities are shown in the provided data. The derivative summary is empty and derivative-related transaction counts are zero, indicating no options, warrants, or similar instruments are reported in this excerpt.